CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Risperidone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00385801
NCT00385801Phase 2Completed

A Double-Blind, Placebo-Controlled Study of the Effects of Risperdal Consta on Brain Reward Circuitry, Craving and Cocaine Use in Active Cocaine Dependence

Massachusetts General Hospital·interventional·Posted Oct 11, 2006·Updated Apr 28, 2017

In Brief

A Phase 2 clinical trial evaluating Risperidone and Placebo for Cocaine Dependence. Completed, enrolled 31 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the effects of the administration of Risperidal-Consta on the brain's reward circuitry using Magnetic resonance Imaging (MRI), behavioral tests and measuring cocaine craving and use among people with active cocaine dependence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsJanssen, LP

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 11, 2006
Enrollment StartSep 1, 2005
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 19.7 years ago

Interventions

Risperidonedrug

Placebodrug